Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 16, 2023

Long-Term Outcomes of Adding Ovarian Suppression to Tamoxifen in Premenopausal Women With HR+ Breast Cancer Who Remain Premenopausal or Resume Ovarian Function After Chemotherapy

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
J. Clin. Oncol 2023 Aug 22;[EPub Ahead of Print], SY Baek, WC Noh, SH Ahn, HA Kim, JM Ryu, SI Kim, EG Lee, SA Im, Y Jung, MH Park, KH Park, SH Kang, J Jeong, E Park, SY Kim, MH Lee, LS Kim, W Lim, S Kim, HJ Kim

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading